A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis Clinical Trial

Official title:
A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis

Status Completed

Clinical Trial Summary

This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Colitis
Colitis, Ulcerative
Moderate to Severe Ulcerative Colitis
Ulcer

Clinical Trial Details

NCT number	NCT04090411
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Completed
Phase	Phase 2
Start date	December 19, 2019
Completion date	October 25, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03627052` - A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis	Phase 2
Recruiting	`NCT05486104` - Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis	Phase 2
Recruiting	`NCT04879966` - A Cohort Study Comparing IFX to CS for Moderate to Severe UC
Terminated	`NCT02092389` - Fecal Calprotectin Levels, QoL and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo	N/A
Completed	`NCT04700449` - A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)	Phase 2